Anti-VEGFR-3 Antibody, Non-Fucosylated (IMC-3C5) (CAT#: BioBet-895ZP) Datasheet

FLT4

fms-related tyrosine kinase 4

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.

FLT4; fms-related tyrosine kinase 4; PCL; FLT41; LMPH1A; VEGFR3; vascular endothelial growth factor receptor 3; FLT-4; VEGFR-3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; fms-like tyrosine kinase 4; tyrosine-protein kinase receptor FLT4

Plasma membrane, Extracellular region or secreted, Nucleus

Diseases associated with FLT4 include Lymphatic Malformation 1 and Congenital Heart Defects, Multiple Types, 7.

Its related pathways are Signaling by GPCR and NF-KappaB Family Pathway.

Tyrosine protein kinase, as the cell surface receptor of VEGFC and VEGFD, plays an important role in the development of vascular network and cardiovascular system during adult lymphangiogenesis and embryonic development. Promote the proliferation, survival and migration of endothelial cells, and regulate the germination of angiogenesis. The activated FLT4 signaling pathway leads to increased production of VEGFC and VEGFA, thereby forming a positive feedback loop that enhances FLT4 signaling. The KDR signal is regulated by the formation of heterodimers. The secreted isoform 3 may act as a decoy receptor for VEGFC and/or VEGFD, and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. The combination of angiogenesis factor with isoform 1 or isoform 2 leads to the activation of several signal cascades; isoform 2 seems to be less efficient in signal transduction because it has a truncated c-terminal and therefore lacks several phosphorylation sites . Mediates the activation of MAPK1/ERK2, MAPK3/ERK1 signaling pathway, MAPK8 and JUN signaling pathway, and AKT1 signaling pathway. Phosphorylate SHC1. Mediates the phosphorylation of PIK3R1, which is the regulatory subunit of phosphatidylinositol 3-kinase. Promote the phosphorylation of MAPK8 in'Thr-183' and'Tyr-185' and the phosphorylation of AKT1 in'Ser-473'.

Cancer antibody; Cell Biology and Cellular Response antibody; Gene Regulation antibody; Signaling Transduction antibody

Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC at Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

IMC-3C5

Human

Human

IMC-3C5 is a human IgG1 monoclonal antibody receptor antagonist designed to bind VEGFR3 and block the binding of VEGF-C and VEGF-D ligands to the receptor, used to treat solid tumors.

Lung cancer (non-small cell); Solid Tumors

Lung cancer (non-small cell); Solid Tumors